ZOM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZOM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Zomedica has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Zomedica Corp shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.GuruFocus does not calculate Zomedica's interest coverage with the available data. Zomedica's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.09. As of today, Zomedica's Altman Z-Score is 5.19.
For the Medical Devices subindustry, Zomedica's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's Financial Strength distribution charts can be found below:
* The bar in red indicates where Zomedica's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Zomedica's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-11.39 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.81 Mil.
Zomedica's Interest Coverage for the quarter that ended in Dec. 2023 is
GuruFocus does not calculate Zomedica's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Zomedica's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
Debt to Revenue Ratio | = | Total Debt (Q: Dec. 2023 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.916 | + | 1.814) | / | 29.348 | |
= | 0.09 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Zomedica has a Z-score of 5.19, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 5.19 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zomedica (AMEX:ZOM) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Zomedica has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Thank you for viewing the detailed overview of Zomedica's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Johnny D Powers | director | C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018 |
Heaton Larry C Ii | officer: President | C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018 |
Russell Kevin Klass | officer: Vice President of Sales | C/O ZOMEDICA CORP, PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108 |
Peter Donato | officer: Chief Financial Officer | 9172 ETON AVENUE, CHATSWORTH CA 91311 |
Pamela Nichols | director | 14841 EAST WILDCAT DR., SCOTTSDALE AZ 85262 |
Karen Dehaan-fullerton | officer: Chief Counsel and Secretary | C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018 |
Anthony K Blair | officer: Chief Operating Officer | NEOPROBE CORPORATION, 425 METRO PLACE NORTH #300, DUBLIN OH 43017 |
Adrian Lock | officer: VP and General Manager | C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018 |
Sean Whelan | director | C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108 |
Robert Cohen | officer: Interim CEO | C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108 |
Ann Cotter | officer: Chief Financial Officer & Sec. | C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108 |
Stephanie Morley | officer: COO & VP of Product Dev | C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108 |
Christopher Ross Macleod | director | C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018 |
Christopher Wolfenberg | director | C/O ZOMEDICA PHARMACEUTICALS CORP, 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108 |
Gerald Jr Solensky | director, 10 percent owner, officer: President and CEO | C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 190, ANN ARBOR MI 48108 |
From GuruFocus
By GuruFocus Research • 05-28-2023
By ACCESSWIRE ACCESSWIRE • 05-08-2023
By ACCESSWIRE • 09-01-2023
By ACCESSWIRE • 12-06-2023
By ACCESSWIRE ACCESSWIRE • 05-13-2023
By ACCESSWIRE ACCESSWIRE • 03-17-2023
By ACCESSWIRE ACCESSWIRE • 05-12-2023
By ACCESSWIRE ACCESSWIRE • 02-09-2023
By ACCESSWIRE ACCESSWIRE • 01-24-2023
By ACCESSWIRE • 10-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.